C
C

Cigna


Hírek

Centene warns of hit to fast-growing Medicare Advantage business next year

UPDATE 3-Centene warns of hit to fast-growing Medicare Advantage business next year Adds company comment from conference call, share movement By Raghav Mahobe and Nandhini Srinivasan Feb 7 (Reuters) - Centene Corp CNC.N on Tuesday said profit at its fast-growing Medicare Advantage (MA) business will take a beating in 2024 due to a sharp cut in its rating by a U.S.
C

Cigna Worldwide Insurance Receives Branch License In Saudi Arabia

BRIEF-Cigna Worldwide Insurance Receives Branch License In Saudi Arabia Feb 6 (Reuters) - Cigna Corp CI.N : CIGNA WORLDWIDE INSURANCE COMPANY RECEIVES BRANCH LICENSE IN SAUDI ARABIA, PLANS GROWTH IN KINGDOM Source text for Eikon: ID:nPrevhsmBa Further company coverage: CI.N
C

U.S. STOCKS Energy index, Church & Dwight, Personalis

BUZZ-U.S. STOCKS ON THE MOVE-Energy index, Church & Dwight, Personalis Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes pared declines by Friday afternoon, as a strong jobs report that initially raised fears of the Federal Reserve keeping interest rates higher for longer also pointed to the resilience in the economy in the face of aggressive policy tightening.
A
A
C
C
G
G
G
M
Q
R
S
S
T
U
U
S
Z
C
C

U.S. STOCKS Gilead Sciences, Regeneron, AlerisLife

BUZZ-U.S. STOCKS ON THE MOVE-Gilead Sciences, Regeneron, AlerisLife Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures dropped on Friday after disappointing results from megacap growth companies including Apple and Amazon, while investors awaited the January jobs report for more clues on future rate hikes by the U.S.
A
A
C
G
G
M
Q
R
S
S
T
U
S

Cigna Corp Says Board Of Directors Declared 10% Increase In Quarterly Dividend Rate To $1.23 Per Share

BRIEF-Cigna Corp Says Board Of Directors Declared 10% Increase In Quarterly Dividend Rate To $1.23 Per Share Feb 3 (Reuters) - Cigna Corp CI.N : CIGNA REPORTS STRONG FOURTH QUARTER AND FULL YEAR 2022 RESULTS, ESTABLISHES 2023 GUIDANCE AND INCREASES DIVIDEND CIGNA CORP - BOARD OF DIRECTORS DECLARED A 10% INCREASE IN QUARTERLY DIVIDEND RATE, TO $1.23
C

Cigna expects revenue gains from launches of Humira biosimilars

UPDATE 2-Cigna expects revenue gains from launches of Humira biosimilars Rewrites, adds management and analyst comments, updates shares By Leroy Leo Feb 3 (Reuters) - Cigna Corp CI.N expects its pharmacy benefit management unit to earn more from the second half of 2023 as makers of cheaper versions of AbbVie Inc's ABBV.N arthritis drug Humira will boost aftermarket discounts to gain access to patients.
A
C

Cigna Corp Reports Fourth Quarter Results

BRIEF-Cigna Corp Reports Fourth Quarter Results Feb 3 (Reuters) - Cigna Corp CI.N : QTRLY TOTAL REVENUES $45.75 BILLION VERSUS $45.69 BILLION; QTRLY ADJUSTED REVENUE $45.74 BILLION VERSUS $45.68 BILLION QTRLY EARNINGS PER SHARE $3.83; QTRLY ADJUSTED EARNINGS PER SHARE $4.96 CIGNA HEALTHCARE MCR OF 84.0% FOR Q4 2022 VERSUS 87.0% Q4 EARNINGS PER SHAR
C

Cigna beats quarterly profit expectations as COVID medical costs fall

Cigna beats quarterly profit expectations as COVID medical costs fall By Leroy Leo Feb 3 (Reuters) - Cigna Corp CI.N beat Wall Street estimates for quarterly profit on Friday, aided by a sharp fall in medical costs due to lower COVID-19-related hospitalizations. Health insurers have largely managed to keep medical costs in check during the fourth quarter amid a so-called "tripledemic" of an early flu season coinciding with COVID and respiratory syncytial virus cases.
C

AbbVie's Humira gets a U.S. rival, but costs could stay high

FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high Updates to clarify lower price may not be widely used, rather than widely available, and why By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited.
A
C

U.S. STOCKS A O Smith, Pentair, health insurers

BUZZ-U.S. STOCKS ON THE MOVE-A O Smith, Pentair, health insurers Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street rose on Tuesday as wage growth data indicated that the Federal Reserve's aggressive approach to taming inflation was taking hold ahead of a decision by the central bank, while gains on the Dow were limited by weak earnings updates.
C
G
I
M
N
P
Q
T
J
U
U
S
A
P

AbbVie's Humira gets a U.S. rival, but costs could stay high

FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high Updates with new CVS policy By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20-year-old drug, with two tiers of pricing.
A
C

AbbVie's Humira gets a U.S. rival, but costs could stay high

FOCUS-AbbVie's Humira gets a U.S. rival, but costs could stay high By Patrick Wingrove Jan 31 (Reuters) - U.S. patients will finally get access to cheaper versions of AbbVie Inc’s ABBV.N blockbuster arthritis drug Humira this year, but the cost savings are expected to be limited. Rival drugmaker Amgen Inc AMGN.O on Tuesday launched Amjevita, the first biosimilar version of AbbVie’s 20-year-old drug, with two tiers of pricing.
A
C

U.S. earnings week ahead

DIARY-U.S. earnings week ahead Jan 27 (Reuters) - Diary of U.S. (.SPX) corporate earnings for the week ahead. ** Please Note - All times given are in U.S. EDT unless otherwise stated ** U.S. EARNINGS Start Date Start Time RIC Company Name Event Name 30-Jan-2023 16:05 WHR Whirlpool Corp Q4 2022 Whirlpool Corp Earnings Release 30-Jan-2023 AMC PFG.O Principal Financial Group Inc Q4 2022 Principal Financial Group Inc Earnings Release 30-Jan-2023 AMC ARE Alexandria Real Estate Equities Inc Q4 2022 Al
A
A
A
C
C
C
D
F
G
G
H
M
M
N
P
P
Q
Q
R
S
A
W
C
E
M
N
T
U
A
A
B
E
I
M
S
T
W
W
Z
A
A
A
A
B
C
C
C
D
F
G
I
O
P
P
S
T

CVS names new pharmacy services, consumer product chiefs

UPDATE 2-CVS names new pharmacy services, consumer product chiefs Adds background on company and new appointments Jan 23 (Reuters) - CVS Health Corp CVS.N said on Monday that David Joyner would return to head the U.S. diversified healthcare company's pharmacy services and tapped former Cigna Corp CI.N executive Amy Bricker as its chief product officer for consumer business.
C

CVS names new pharmacy services, consumer products chiefs

CVS names new pharmacy services, consumer products chiefs Jan 23 (Reuters) - CVS Health Corp CVS.N named David Joyner to head its pharmacy services and appointed former Cigna Corp CI.N executive Amy Bricker as chief product officer for consumer businesses, the company said on Monday. Reporting by Raghav Mahobe and Sriparna Roy in Bengaluru
C

Evernorth Names Adam Kautzner President, Express Scripts

BRIEF-Evernorth Names Adam Kautzner President, Express Scripts Jan 18 (Reuters) - Cigna Corp CI.N : EVERNORTH NAMES ADAM KAUTZNER PRESIDENT, EXPRESS SCRIPTS Source text for Eikon: ID:nPn6jQ9Qda Further company coverage: CI.N
C

Wall St set to open lower as earnings of big banks disappoint

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.) * JPMorgan reports profit miss * June PPI surges more than expected * Futures down: Dow 1.55%, S&P 1.29%, Nasdaq 0.82% By Amruta Khandekar and Bansari Mayur Kamdar July 14 (Reuters) - U.S. stocks were set to open lower on Thursday as downbeat earnings from big U.S.
C
G
U
U

Futures fall as JPMorgan, Morgan Stanley kick off earnings on sour note

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window.) * Futures down: Dow 1.35%, S&P 1.27%, Nasdaq 0.88% By Amruta Khandekar and Bansari Mayur Kamdar July 14 (Reuters) - U.S. stock index futures fell on Thursday after JPMorgan Chase & Co and Morgan Stanley kicked off the earnings season with downbeat results, adding to worries of a potential recession.
C
G
U
U

How far behind the curve exactly?

A look at the day ahead in markets from Julien Ponthus. On Friday, St. Louis Fed President James Bullard argued that the U.S. Federal Reserve is "not as far behind the curve as you might have thought". With inflation running over 6%, the jury is out on whether last week's 50 basis point rate hike is catching up with the curve or falling woefully behind.
A
C
U

Sell everything (except the dollar)!

A look at the day ahead in markets from Dhara Ranasinghe. When the blue-chip Dow Jones index slides more than 1,000 points on one day, U.S. Treasury yields jump as much as 20 basis points and Britain's pound drops more than 2%, you'd be forgiven for thinking that investors have gone into a sell everything mode. But with the safe-haven dollar at 20-year highs, there was at least one asset benefiting from Thursday's market mayhem.
A
C
U



Feltételek

Népszerű eszközök

Felelősségkizáró nyilatkozat: Az XM Group entitásai csak végrehajtási szolgáltatást és online kereskedési platformunkhoz való hozzáférést biztosítanak, ami lehetővé teszi, hogy a felhasználók megtekinthessék és/vagy felhasználhassák a honlapon vagy azon keresztül elérhető tartalmakat, amelyek nem módosíthatók és nem egészíthetők ki. A hozzáférés és felhasználás mindig a következők függvénye: (i) Felhasználási feltételek; (ii) Kockázati figyelmeztetés; valamint (iii) Teljes felelősségkizáró nyilatkozat. Az ilyen tartalmakat ezért csupán általános információként biztosítjuk. Külön felhívjuk figyelmét arra, hogy az online kereskedési platformunkon található tartalmak nem felhívások vagy ajánlatok tranzakciókba történő belépésre a pénzügyi piacokon. A pénzügyi piacokon folytatott kereskedés jelentős kockázattal jár a tőkéjére nézve.

Az online kereskedési platformunkon közzétett anyagok kizárólag oktatási / tájékoztatási célt szolgálnak, és nem tartalmaznak (nem tekinthető úgy, hogy tartalmaznak) pénzügyi, befektetési adóügyi vagy kereskedési tanácsokat vagy ajánlásokat, illetve kereskedési áraink jegyzékét, vagy bármilyen pénzügyi instrumentummal végrehajtott tranzakcióra vonatkozó ajánlatot vagy felhívást, vagy Önnek szóló kéretlen pénzügyi promóciókat.

Az ezen a honlapon szereplő, külső felektől származó, valamint az XM által készített tartalmak, például vélemények, hírek, kutatások, elemzések, árak és egyéb információk vagy külső felek oldalaira utaló hivatkozások „jelenlegi állapotukban”, általános piaci magyarázatként jelennek meg, és nem minősülnek befektetési tanácsnak. Amennyiben bármely tartalom befektetéssel kapcsolatos kutatásként értelmezhető, meg kell értenie és el kell fogadnia, hogy a tartalom nem a befektetéssel kapcsolatos kutatás függetlenségének előmozdítására szolgáló jogi követelmények szerint készült, következésképpen a vonatkozó törvények és jogszabályok szerint marketingkommunikációnak minősül. Kérjük, feltétlenül olvassa el és értse meg a fenti információkkal kapcsolatos „nem független befektetéskutatással kalcsolatos tájékoztatónkat” és a kockázati figyelmeztetésünket, amelyek itt érhetők el.

Honlapunkon a legjobb felhasználói élmény biztosítása érdekében sütiket használunk. Tájékozódjon a részletekről, vagy módosítsa süti beállításait.

Kockázati figyelmeztetés: a tőkeáttételes termékekkel folytatott kereskedés jelentős kockázatnak teszi ki befektetett tőkéjét, és nem feltétlenül megfelelő minden befektető számára. Kérjük, olvassa el a kockázati figyelmeztetés erre vonatkozó részleteit.